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Because glucocorticoid excess increases neuronal vulnerability, genetic variations in the glucocorticoid
systemmay be related to the risk for Alzheimer’s disease (AD). We analyzed single-nucleotide polymorphisms
in 10 glucocorticoid-related genes in a population of 814 AD patients and unrelated control subjects. Set-
association analysis revealed that a rare haplotype in the 50 regulatory region of the gene encoding
11b-hydroxysteroid dehydrogenase type 1 (HSD11B1) was associated with a 6-fold increased risk for sporadic
AD. Results of a reporter-gene assay indicated that the rare risk-associated haplotype altered HSD11B1
transcription. HSD11B1 controls tissue levels of biologically active glucocorticoids and thereby inﬂuences
neuronal vulnerability. Our results indicate that a functional variation in the glucocorticoid system increases
the risk for AD, which may have important implications for the diagnosis and treatment of this disease.
INTRODUCTION
Alzheimer’s disease (AD) is the major neurodegenerative
disorder of the elderly, and is characterized by progressive
cognitive deficits such as impairment of memory.
Histopathologically, AD is characterized by extracellular
b-amyloid plaques, intraneuronal neurofibrillary tangles,
synaptic loss and neuronal death. Hippocampal neurons are
among the first cells to degenerate in the brain of patients
affected by AD (1). The hippocampus is a brain region
important for memory (2) and contains a high density of
glucocorticoid receptors (3,4). Glucocorticoids are known to
influence cognitive functions (5–9) and high concentrations of
these steroid hormones have adverse effects on neurons,
especially in the hippocampus, and reduce neuronal ability to
survive a variety of coincident insults, including AD-associated
neurotoxicity (10–12). Therefore, increased circulating hydro-
cortisone concentrations, which are consistently found in AD
(9,13–16), may play a role in the pathophysiology of this
disease. The possibility that the glucocorticoid system may be
implicated in AD led us to hypothesize that polymorphisms in
genes involved in the regulation of the glucocorticoid system
may influence the risk for this disease.
In a case–control study in two independent, ethnically
distinct populations, we investigated single nucleotide poly-
morphisms (SNPs) in genes coding for the following proteins:
corticotropin-releasing hormone (CRH), corticotropin-releasing
hormone binding protein (CRHBP), receptor for the adreno-
corticotropic hormone (MC2R), 11b-hydroxysteroid dehydro-
genase type 1 and 2 (HSD11B1, HSD11B2), glucocorticoid
receptor (NR3C1), glucocorticoid modulatory element binding
protein 1 and 2 (GMEB1, GMEB2), steroidogenic factor 1
(NR5A1) and nuclear receptor coactivator 2 (NCOA2).
For statistical analysis, we used the set-association method
(17) which evaluates accurately several sets of polymorphic
markers. To date, case–control association studies mostly
follow a candidate-gene approach by examining one gene at a
time. Although powerful, this approach ignores the genetic
complexity of sporadic AD, which is caused by variations in
several genes, each with a small effect on overall disease risk.
Moreover, this marker-by-marker procedure causes severe
inflation of the type I statistical error (i.e. false positive results)
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due to multiple testing in one population and overlooks
possible interactions between susceptibility genes. By simulta-
neous analysis of several polymorphic markers, the set-
association method controls for type I statistical error and
considers the existence of gene–gene interactions.
RESULTS
Genotyping of 11 SNPs in glucocorticoid-related genes
(Table 1) and of the gene encoding apolipoprotein E (APOE)
in 814 individuals revealed that two genes, APOE and
HSD11B1, were associated with AD. The level of significance
reached by these two genes was equal to 0.002 (Fig. 1A). The
final corrected significance Pmin was 0.006. Family history for
AD or dementia did not influence the results. Separate set-
association analysis in the Swiss and Mediterranean samples
revealed similar results, i.e. APOE and HSD11B1 contributed
to AD risk (Fig. 1B and C). In the Mediterranean sample
(n¼ 423), the gene encoding the adrenocorticotropic hormone
receptor (MC2R) was also associated with the disease (Fig. 1C).
Set-association analysis excluding APOE confirmed that,
among the examined glucocorticoid-related genes, only
HSD11B1 is a susceptibility gene for AD (Fig. 1D).
Conventional w2 analysis also revealed significant over-
representation (P¼ 0.008) of the rare allele A of HSD11B1
(rs846911) in AD patients (2.9%) as compared with control
subjects (0.5%). This difference corresponded to an odds ratio
(OR) of 6.2 [95% confidence interval (CI): 1.4–28.4]. The
APOE4 allele was also more frequent in AD patients (48.0%)
than in control subjects (25.4%, P< 0.000001), corresponding
to an OR of 3.0 (95% CI: 2.1–3.5). In addition to rs846911,
which is located 2037 bp upstream of the start codon of
HSD11B1, we also analyzed rs860185, which is located 718 bp
upstream of the start codon, and observed that both SNPs had
identical allelic frequencies and were in complete linkage
disequilibrium (LD). Thus, recombination events in the 50
regulatory region of HSD11B1, at least up to 2 kb upstream of
the start codon, were absent in 814 individuals. This region is
characterized by two extended haplotypes spanning 1.3 kb, the
rare and disease-associated haplotype A-T and the frequent
haplotype C-A (Fig. 2).
To exclude the possibility that the observed association is due
to LD of the HSD11B1 haplotype with SNPs in the 50 and 30
adjacent genes, we genotyped part of our population for SNPs
rs713073 and rs926346, located in CAMK1G (encoding
calcium/calmodulin-dependent protein kinase 1G) and IRF6
(encoding interferon regulatory factor 6), respectively, and
failed to observe a significant association of either SNP with
AD (P 0.15, Fig. 2). To further exclude the possibility of LD
with yet not identified SNPs in HSD11B1, we sequenced in 24
chromosomes the six exons of HSD11B1, the intron–exon
boundaries and 2.1 kb upstream the start codon. Eight of the 24
chromosomes contained the disease-associated haplotype.
We found no evidence for additional coding SNPs or those
influencing RNA splicing. Sequencing of 2.1 kb upstream
the start codon revealed the absence of SNPs other than
rs846911 and rs860185.
Taken together, these results suggest that the haplotype
spanning SNPs rs846911 and rs860185 is directly associated
with the risk for AD. To determine the effects of this haplotype
on transcriptional regulation, we cloned haplotype-specific
promoter fragments into the pGL3-Basic vector. Promoter
activity was assayed using a dual-luciferase system in human
embryonic kidney cells (HEK-293). The risk-associated, rare
haplotype reduced luciferase activity by 20% relative to the
common haplotype (P< 0.000001), suggesting that the effects
of the rare haplotype on AD risk are related to reduced
HSD11B1 transcription (Fig. 3).
DISCUSSION
The results of the present study revealed that a rare haplotype in
the 50 regulatory region of the gene encoding HSD11B1 was
associated with increased risk for sporadic AD. We did not find
evidence for another causal SNP in the 50 and 30 adjacent genes,
the six exons, the intron–exon boundaries or 2.1 kb upstream the
start codon of HSD11B1. Moreover, we did not find strong
evidence for association of other glucocorticoid-related genes
with AD. Because we investigated one SNP per gene on average,
however, the possibility still exists that unlinked causal genetic
loci could have been missed. In addition, extensive sequencing of
the broader 50 region of HSD11B1 beyond the already sequenced
2.1 kb should follow to define the exact haplotype borders and to
detect possible additional SNPs associated with AD. Thus, the
negative results presented herein do not justify definite exclusion
of specific glucocorticoid-related genomic regions as significant
susceptibility factors for AD.
We also found evidence for a functional relevance of the rare,
disease-associated haplotype. In particular, the results of a
reporter-gene assay indicated that the disease-associated
haplotype reduced HSD11B1 transcription. HSD11B1 is an
intracellular enzyme which catalyses the interconversion of
glucocorticoids and thereby controls tissue levels of biologically
active glucocorticoids. While in cell culture HSD11B1 seems to
act predominantly as a reductase (18), this enzyme favors
dehydrogenase activity in cell homogenates, where cells are
damaged, resulting in inactivation of biologically active
glucocorticoids (19–21). Moreover, an in vivo study has shown
potent dehydrogenase activity of HSD11B1 in the rat
hippocampus (22). In the present study, carriers of the rare
haplotype with reduced HSD11B1 transcription may therefore
show less inactivation of hydrocortisone resulting in increased
neuronal vulnerability to AD-associated neurotoxicity and,
finally, in increased risk for the clinical manifestation of AD.
Our results further suggest that increased circulating
hydrocortisone concentrations, which are consistently found
in AD (9,13–16) may play a role in the pathophysiology of this
disease.
In summary, we report first evidence for a genetic association
between the glucocorticoid system and AD. Importantly, results
of a reporter-gene assay indicate that the rare risk-associated
haplotype alters HSD11B1 transcription. HSD11B1 controls
tissue levels of biologically active glucocorticoids which are
known to influence neuronal vulnerability (10–12). Owing to
the strong effect on the risk for AD, this haplotype may have a
potential value as a diagnostic marker with high positive
predictive value. Because this is the first study reporting an
association between a glucocorticoid-related gene and AD,
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independent replications will be crucial to corroborate the
results, which may have important implications for therapeutic
approaches aimed at preventing neurodegeneration in AD.
MATERIALS AND METHODS
Population
Genetic studies were conducted in two independent popula-
tions: a Swiss sample (391 participants) and a Mediterranean
sample (423 participants from Italy and Northern Greece).
Patients were recruited from the outpatient memory clinics of
the participating institutions. The clinical diagnoses of AD
(n¼ 351) were made according to the NINCDS-ADRDA
criteria, and were based on medical interview, physical
examination, neuropsychological testing, brain MRI or CT, as
well as blood and CSF tests. The mean onset age (standard
deviation) of AD was 67 9 years, the mean Mini-mental State
Examination (MMSE) score was 20 6. There were 211 (60%)
females among the AD patients. Family history information
was obtained by direct interview of the patients and their
care-givers on the occurrence of AD, dementia and signs of
memory loss in the first degree relatives of the patients and was
positive for 49.3% of the participants. The control group
(n¼ 463) consisted of elderly individuals without severe
medical conditions who were either the spouses of AD patients
or subjects recruited from the outpatient clinics of the
participating institutions. Dementia and memory deficits in
control subjects were excluded by neuropsychological testing,
consisting of the CERAD neuropsychological test battery and
the MMSE. The mean age was 68 9 years, the mean MMSE
score was 29 1. There were 245 (53%) females among the
control subjects. Informed consent was obtained from all
participants, and the local human studies committees approved
the study protocol.
Table 1. Genotype distributions of SNPs included in the final step of set-association analysis. Two SNPs (rs915032 in NR5A1 and rs877181 in NCOA2) were not
considered due to significant deviations from Hardy–Weinberg equilibrium (P< 0.05) in control subjects














AA 93.9% 95.2% 93.9% 95.2% 93.9% 95.2%
AG 6.1% 4.8% 6.1% 4.8% 6.1% 4.8%
GG — — — — — —
rs2318376 (GMEB1)
AA 34.6% 37.4% 43.5% 40.6% 38.2% 39.7%
AG 45.2% 38.4% 41.7% 46.3% 43.8% 44.0%
GG 20.2% 24.2% 14.8% 13.1% 18.0% 16.3%
rs914563 (GMEB2)
CC 95.1% 94.2% 95.7% 94.8% 95.4% 94.6%
CT 4.9% 5.8% 3.7% 5.2% 4.4% 5.4%
TT — — 0.6% — 0.2% —
rs2272725 (NCOA2)
GG 87.1% 89.4% 88.0% 86.3% 87.5% 87.2%
GC 12.5% 10.6% 12.0% 13.3% 12.3% 12.5%
CC 0.4% — — 0.4% 0.2% 0.3%
rs948322 (MC2R)
AA 11.8% 9.7% 14.3% 7.2% 12.7% 8.0%
AG 45.2% 50.5% 44.7% 45.8% 45.1% 47.2%
GG 43.0% 39.8% 41.0% 47.0% 42.2% 44.8%
rs6159 (CRH)
AA 77.4% 78.6% 74.2% 80.2% 76.2% 79.8%
AC 21.4% 19.4% 23.3% 18.0% 22.1% 18.5%
CC 1.2% 1.9% 2.5% 1.6% 1.7% 1.7%
rs32897 (CRHBP)
GG 4.1% — 1.8% 4.9% 3.2% 3.5%
GA 24.2% 29.3% 27.0% 25.5% 25.3% 26.6%
AA 71.7% 70.7% 71.2% 69.5% 71.5% 69.9%
rs846911 (HSD11B1)
AA — — — — — —
AC — 1.0% 1.2% 3.6% 0.5% 2.9%
CC 100% 99.0% 98.8% 96.4% 99.5% 97.1%
rs5479 (HSD11B2)
CC 92.2% 94.1% 89.6% 86.3% 91.2% 88.6%
CA 7.8% 5.9% 10.4% 13.3% 8.8% 11.1%
AA — — — 0.4% — 0.3%
SNP, single-nucleotide polymorphism according to dbSNP; HCS, healthy control subjects; AD, patients with Alzheimer’s disease; gene names are given in
parentheses.
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Genotyping
Information on polymorphic sites was derived from the
database of single nucleotide polymorphisms (dbSNP)
established by the National Center for Biotechnology
Information (www.ncbi.nlm.nih.gov/SNP/index.html). Twenty-
one SNP candidates in 10 genes were selected for genotyping.
Of these SNP candidates, eleven were polymorphic in 100
chromosomes (rs915032 in NR5A1, rs6195 in NR3C1,
rs2318376 in GMEB1, rs914563 in GMEB2, rs2272725 and
rs877181 in NCOA2, rs948322 in MC2R, rs6159 in CRH,
rs32897 in CRHBP, rs846911 in HSD11B1, and rs5479 in
HSD11B2) and were genotyped in the study sample by the
MasscodeTM system (23). APOE genotyping was done on the
LightCyclerTM (24).
Statistics
We used the SUMSTAT program (http://linkage.rockefeller.
edu/ott/sumstat.html), which has been developed for the
statistical analysis with the set-association method (17). The
set-association method combines the information derived from
measurements of allelic association and deviation from
Hardy–Weinberg equilibrium into a single, genome-wide
statistic. SNPs with high Hardy–Weinberg disequilibrium
Figure 1. Significance level P as a function of SNPs in glucocorticoid-related genes and in APOE. SNPs were added to the model stepwise according to their
contribution to the disease risk. SNPs decreasing P-value to a minimum (black bars) exert a significant effect. White bars indicate SNPs not contributing to
the disease risk significantly, i.e. P-value is increasing due to introduction of statistical noise. (A) total sample (n¼ 814); (B) Swiss sample (n¼ 391); (C)
Mediterranean sample (n¼ 423); (D) total sample excluding APOE.
Figure 2. Schematic representation of the HSD11B1 region and of the analyzed SNPs. All distances are given relative to the HSD11B1 start codon, rs numbers
represent the reference sequence numbers according to the dbSNP. HSD11B1 is shown in gray with short vertical lines representing the exons. CAMK1G and IRF6
are the 50 and 30 adjacent genes to HSD11B1, respectively.
50 Human Molecular Genetics, 2004, Vol. 13, No. 1
(HWD) values in the control population are set equal to zero
(‘trimming’) and are not considered for further statistical
analysis. For the remaining SNPs, effects of allelic association
with disease and HWD values are combined into one statistic,
because moderate HWD values in affected individuals are
indicative of genetic association to a susceptibility locus (17).
Genome-wide significance of this statistic is calculated by
permutation tests. In the present study, two SNPs with high
HWD values (w2> 3.9, P< 0.05) in the control population
were trimmed. The number of permutation tests was set at
50 000.
Reporter-gene assay
A 2.1 kb long fragment of the human HSD11B1 regulatory
region (accession number: NT_021877), containing the
common haplotype (C-A), was generated by gene synthesis
(Medigenomix, Martiensried, Germany), cloned into the
BlueScript vector (Stratagene) and subsequently into the
promoter-less pGL3-Basic vector (Promega). A site-directed
mutagenesis kit (Stratagene) was used to generate the construct
containing the rare haplotype (A-T). Several DNA clones
containing the A-T haplotype were selected. All constructs
were verified by sequence analysis.
Human embryonic kidney cells (HEK, 293) were cultured
in DMEM (Life Technologies) supplemented with 10% FBS,
50 units/ml penicillin and 50 mg/ml streptomycin. Transfection
of 90% confluent cultures, grown in 24-well plates, was
performed with lipofectamine 2000 (Invitrogene), using 1.5 mg
DNA per well. Firefly luciferase expressing constructs
containing the common or rare haplotype in the human
HSD11B1 regulatory region were co-transfected in a molar
ratio of 150:1 with pRL-TK renilla luciferase vector
(Promega) as the internal control for transfection efficiency.
Twenty-four hours later, cells were harvested with the passive
lysis buffer of the Dual-Luciferase system (Promega) and the
luciferase activities were measured according to the manu-
facturer’s protocol. After deduction of background values
(luciferase activity of the promoterless PGL3 vector), the ratio
of firefly to renilla activities was calculated and the average
were built for each group. Experiments were repeated in 20
independent wells.
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